Biomarkers /
IGH
Overview
Immunoglobulin heavy locus (IGH) is a gene that encodes for a variable region in immunoglobulins, protein complexes that recognize foreign antigens and initiate immune responses. It is not clear whether IGH mutations have been observed in human cancers.
IGH is altered in 0.62% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, follicular lymphoma, mature B-cell neoplasm, breast invasive ductal carcinoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma having the greatest prevalence of alterations [3].
The most common alterations in IGH are IGH Fusion (0.32%), IGH-BCL2 Fusion (0.29%), IGH-MYC Fusion (0.23%), IGH-CCND1 Fusion (0.15%), and IGH-FGFR3 Fusion (0.08%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of IGH in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.